Cargando…

Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection

The goal of this study was to investigate the serological titers of circulating antibodies against human papillomavirus (HPV) type 16 (anti-HPV16) prior to the detection of an incident HPV16 or HPV31 infection amongst vaccinated participants. Patients were selected from a prospective post-HPV vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales: Gradissimo, Ana, Shankar, Viswanathan, Wiek, Fanua, St. Peter, Lauren, Studentsov, Yevgeniy, Nucci-Sack, Anne, Diaz, Angela, Pickering, Sarah, Schlecht, Nicolas F., Burk, Robert D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402915/
https://www.ncbi.nlm.nih.gov/pubmed/34452413
http://dx.doi.org/10.3390/v13081548
_version_ 1783745905608884224
author Gradissimo, Ana
Shankar, Viswanathan
Wiek, Fanua
St. Peter, Lauren
Studentsov, Yevgeniy
Nucci-Sack, Anne
Diaz, Angela
Pickering, Sarah
Schlecht, Nicolas F.
Burk, Robert D.
author_facet Gradissimo, Ana
Shankar, Viswanathan
Wiek, Fanua
St. Peter, Lauren
Studentsov, Yevgeniy
Nucci-Sack, Anne
Diaz, Angela
Pickering, Sarah
Schlecht, Nicolas F.
Burk, Robert D.
author_sort Gradissimo, Ana
collection PubMed
description The goal of this study was to investigate the serological titers of circulating antibodies against human papillomavirus (HPV) type 16 (anti-HPV16) prior to the detection of an incident HPV16 or HPV31 infection amongst vaccinated participants. Patients were selected from a prospective post-HPV vaccine longitudinal cohort at Mount Sinai Adolescent Health Center in Manhattan, NY. We performed a nested case–control study of 43 cases with incident detection of cervical HPV16 (n = 26) or HPV31 (n = 17) DNA who had completed the full set of immunizations of the quadrivalent HPV vaccine (4vHPV). Two control individuals whom had received three doses of the vaccine (HPV16/31-negative) were selected per case, matched on age at the first dose of vaccination and follow-up time in the study: a random control, and a high-risk control that was in the upper quartile of a sexual risk behavior score. We conducted an enzyme-linked immunosorbent assay (ELISA) for the detection of immunoglobulin G (IgG) antibodies specific to anti-HPV16 virus-like particles (VLPs). The results suggest that the average log antibody titers were higher among high-risk controls than the HPV16/31 incident cases and the randomly selected controls. We show a prospective association between anti-HPV16 VLP titers and the acquisition of an HPV16/31 incident infection post-receiving three doses of 4vHPV vaccine.
format Online
Article
Text
id pubmed-8402915
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84029152021-08-29 Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection Gradissimo, Ana Shankar, Viswanathan Wiek, Fanua St. Peter, Lauren Studentsov, Yevgeniy Nucci-Sack, Anne Diaz, Angela Pickering, Sarah Schlecht, Nicolas F. Burk, Robert D. Viruses Article The goal of this study was to investigate the serological titers of circulating antibodies against human papillomavirus (HPV) type 16 (anti-HPV16) prior to the detection of an incident HPV16 or HPV31 infection amongst vaccinated participants. Patients were selected from a prospective post-HPV vaccine longitudinal cohort at Mount Sinai Adolescent Health Center in Manhattan, NY. We performed a nested case–control study of 43 cases with incident detection of cervical HPV16 (n = 26) or HPV31 (n = 17) DNA who had completed the full set of immunizations of the quadrivalent HPV vaccine (4vHPV). Two control individuals whom had received three doses of the vaccine (HPV16/31-negative) were selected per case, matched on age at the first dose of vaccination and follow-up time in the study: a random control, and a high-risk control that was in the upper quartile of a sexual risk behavior score. We conducted an enzyme-linked immunosorbent assay (ELISA) for the detection of immunoglobulin G (IgG) antibodies specific to anti-HPV16 virus-like particles (VLPs). The results suggest that the average log antibody titers were higher among high-risk controls than the HPV16/31 incident cases and the randomly selected controls. We show a prospective association between anti-HPV16 VLP titers and the acquisition of an HPV16/31 incident infection post-receiving three doses of 4vHPV vaccine. MDPI 2021-08-05 /pmc/articles/PMC8402915/ /pubmed/34452413 http://dx.doi.org/10.3390/v13081548 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gradissimo, Ana
Shankar, Viswanathan
Wiek, Fanua
St. Peter, Lauren
Studentsov, Yevgeniy
Nucci-Sack, Anne
Diaz, Angela
Pickering, Sarah
Schlecht, Nicolas F.
Burk, Robert D.
Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection
title Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection
title_full Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection
title_fullStr Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection
title_full_unstemmed Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection
title_short Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection
title_sort anti-hpv16 antibody titers prior to an incident cervical hpv16/31 infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402915/
https://www.ncbi.nlm.nih.gov/pubmed/34452413
http://dx.doi.org/10.3390/v13081548
work_keys_str_mv AT gradissimoana antihpv16antibodytiterspriortoanincidentcervicalhpv1631infection
AT shankarviswanathan antihpv16antibodytiterspriortoanincidentcervicalhpv1631infection
AT wiekfanua antihpv16antibodytiterspriortoanincidentcervicalhpv1631infection
AT stpeterlauren antihpv16antibodytiterspriortoanincidentcervicalhpv1631infection
AT studentsovyevgeniy antihpv16antibodytiterspriortoanincidentcervicalhpv1631infection
AT nuccisackanne antihpv16antibodytiterspriortoanincidentcervicalhpv1631infection
AT diazangela antihpv16antibodytiterspriortoanincidentcervicalhpv1631infection
AT pickeringsarah antihpv16antibodytiterspriortoanincidentcervicalhpv1631infection
AT schlechtnicolasf antihpv16antibodytiterspriortoanincidentcervicalhpv1631infection
AT burkrobertd antihpv16antibodytiterspriortoanincidentcervicalhpv1631infection